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ABSTRACT
Metformin is the frontline therapy for type II diabetes mellitus.
The oral bioavailability of metformin is unexpectedly high, be-
tween 40 and 60%, given its hydrophilicity and positive charge
at all physiologic pH values. Previous studies in Caco-2 cell
monolayers, a cellular model of the human intestinal epithelium,
showed that during absorptive transport metformin is taken up
into the cells via transporters in the apical (AP)membrane; however,
predominant transport to the basolateral (BL) side occurs via the
paracellular route because intracellular metformin cannot egress
across the BL membrane. Furthermore, these studies have sug-
gested that the AP transporters can contribute to intestinal
accumulation and absorption of metformin. Transporter-specific
inhibitors as well as a novel approach involving a cocktail of
transporter inhibitors with overlapping selectivity were used to
identify the AP transporters that mediate metformin uptake in
Caco-2 cell monolayers; furthermore, the relative contributions of
these transporters in metformin AP uptake were also determined.
The organic cation transporter 1, plasma membrane monoamine
transporter (PMAT), serotonin reuptake transporter, and choline
high-affinity transporter contributed to approximately 25%, 20%,
20%, and 15%, respectively, of the AP uptake of metformin. PMAT-
knockdown Caco-2 cells were constructed to confirm the contribu-
tion of PMAT in metformin AP uptake because a PMAT-selective
inhibitor is not available. The identification of four intestinal trans-
porters that contribute to AP uptake and potentially intestinal
absorption of metformin is a significant novel finding that can in-
fluence our understanding of metformin pharmacology and in-
testinal drug-drug interactions involving this highly prescribed drug.
Introduction
Metformin is a widely prescribed antihyperglycemic agent
for the treatment of type II diabetes mellitus. Despite its
reputation as the front line antidiabetic agent, little is known
about the intestinal absorption mechanism of this very hy-
drophilic drug (logD at pH 7.4 of 26.13) that is positively
charged (pKa 12.4) at physiologic pH (Saitoh et al., 2004). The
physicochemical properties of metformin do not promote ef-
ficient membrane permeation by passive diffusion, which
should result in poor intestinal absorption unless its intestinal
absorption is mediated by transporters. Metformin exhibits high
but variable oral bioavailability 40–60% (Pentikäinen et al., 1979;
Tucker et al., 1981) and undergoes flip-flop kinetics, where
absorption is the rate-limiting step in its elimination following
oral administration (Pentikäinen et al., 1979; Tucker et al., 1981).
Furthermore, oral absorption of metformin is dose dependent
(Noel, 1979; Pentikäinen et al., 1979; Tucker et al., 1981;
Karttunen et al., 1983; Pentikäinen, 1986). These results are
consistent with the hypothesis that oral absorption of metformin
is mediated by transporters.
We have investigated the mechanism of intestinal absorp-
tion of metformin in the well established model of human
intestinal epithelium, the Caco-2 cell monolayers (Proctor
et al., 2008). The study showed that metformin was taken up
efficiently across the apical (AP) membrane of Caco-2 cells by
bidirectional cation-selective transporter(s) during absorptive
transport. However, efflux of this drug across the basolateral
(BL) membrane of Caco-2 cell monolayers was inefficient,
resulting in accumulation in Caco-2 cells. We have proposed
that after an oral dose,metformin is taken up byAP transporters
into enterocytes, accumulated in the intestinal epithelium, and
cycled between the enterocytes and intestinal lumen via AP
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uptake and efflux transporters; thus, availing multiple opportu-
nities for efficient absorption via the paracellular route (Proctor
et al., 2008).
The present study was undertaken to identify the cation-
selective transporters that facilitate AP uptake of metformin
in Caco-2 cell monolayers, and to determine their relative
contributions toward metformin AP uptake. This was achieved
by employing a combination of chemical inhibitors, both in-
dividually and as a cocktail, at concentrations that selectively
inhibit the activity of transporters that were expected to be
involved in the uptake of metformin. This study reports a novel
but simple method to determine the relative contribution of four
putative transporters, organic cation transporter 1 (OCT1),
plasma membrane monoamine transporter (PMAT), serotonin
reuptake transporter (SERT), and choline high-affinity trans-
porter (CHT), in the overall AP uptake of metformin into Caco-2
cell monolayers.
Materials and Methods
Eagle’s minimum essential medium with Eagle’s salts and
L-glutamate, F-12 Nutrient Mixture, HEPES (1 M), penicillin-
streptomycin-amphotericin B solution (100), nonessential amino
acids (100), geneticin, SuperScript III First-Strand Synthesis
SuperMix, TaqMan Gene Expression Master Mix, and TaqMan Gene
Expression Assays for OCT1, 2, 3, PMAT, multidrug and toxin
extrusion (MATE) 1 and 2, SERT, CHT, and choline transporter–like
protein (CTL) 1–5 were obtained from Life Technologies (Carlsbad,
CA). Hanks’ balanced salt solution with calcium and magnesium was
purchased from Mediatech, Inc. (Mannassas, VA). Hygromycin B
solution was obtained from Roche Applied Science (Indianapolis, IN).
Total RNA from normal human intestinal tissue was purchased from
Zyagen (San Diego, CA). Fetal bovine serum (FBS), dialyzed FBS
(mol. wt. cut-off 10,000), trypsin-EDTA (1), cimetidine, mitoxantrone,
corticosterone, desipramine, 1-methyl-4-phenylpyridinium (MPP1),
paroxetine, and hemicholinium-3 (HC3) were purchased from Sigma-
Aldrich (St. Louis, MO). [14C]Metformin was purchased from Moravek
Biochemicals and Radiochemicals (Brea, CA). [3H]Serotonin was
purchased from PerkinElmer (Waltham, MA). OCT1–3, novel organic
cation transporter 2 (OCTN2), and mock transfected Chinese hamster
ovary (CHO) cells were previously generated and characterized in our
laboratory (Ming et al., 2009). The Caco-2 (HTB-37) cell line was
obtained from the American Type Culture Collection (Manassas, VA).
Human OCT1-knockdown Caco-2 clones were generated in our lab-
oratory previously (Han et al., 2013). SERT transfected human em-
bryonic kidney 293 (HEK 293) cells were provided by Dr. Randy Blakely
fromVanderbilt University (Nashville, TN). Control HEK 293 cells were
purchased from the Tissue Culture Facility at the University of North
Carolina at Chapel Hill (Chapel Hill, NC). A radioimmunoprecipitation
assay buffer system, rabbit anti-human OCT1 and SERT antibodies,
goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Dallas, TX),
MOPS (4-morpholinepropanesulfonic acid) SDS running buffer stock,
MOPS transfer buffer stock, protein ladder, protein gels, polyvinylidene
difluoride Filter Paper Sandwich (Life Technologies, Grand Island,
NY), Rabbit anti-human PMAT antibody and SuperSignal West Dura
Chemiluminescent Substrate (Thermo Scientific, Waltham, MA),
rabbit anti-human CHT antibody (Antibodies-Online, Atlanta, GA),
and Western blot imaging system (Bio-Rad Laboratories, Hercules,
CA) were purchased from the indicated sources.
Culturing of OCT-Expressing CHO Cells, SERT-Expressing
HEK 293 Cells, and Caco-2 Cells
CHO cells that were stably expressing OCT1, OCT2, OCT3,
OCTN2, and vector-control cells (mock) were cultured, and transport
experiments were performed as described previously (Ming et al.,
2009). Briefly, cells were cultured in F-12 Nutrient Mixture supple-
mented with 10%FBS, 100 units/ml penicillin, 100mg/ml streptomycin,
and 0.25 mg/ml amphotericin B with an additional 500 mg/ml geneticin
forOCT1-3 andmock CHO cells or 200mg/ml hygromycinB forOCTN2-
CHO cells. The cells were passaged following 90% confluence using
trypsin-EDTA, and plated at a 1:20 ratio in 75 cm2 T-flasks.
Caco-2 cells were cultured as described previously (Proctor et al.,
2008). Briefly, the cells (passage numbers 30–40) were seeded at
a density of 60,000 cells/cm2 on polycarbonate membranes of Trans-
wells (Corning Inc., Tewksbury, MA). The culture medium was
changed the day following seeding and every other day thereafter.
Cell monolayers with transepithelial electrical resistance (TEER)
greater than 300 V·cm2 were used for experimentation at 21–28 days
postseeding. TEER values were measured before and after each
experiment, and values greater than 300 V·cm2 indicated that
metformin or transporter inhibitors used in the experiment did not
affect cell viability and/or the integrity of the cell monolayers.
SERT-transfected HEK 293 cells and control parental HEK 293
lines were maintained in monolayer cultures in 75 cm2 flasks in an
atmosphere of 5% CO2 at 37°C as described previously (Qian et al.,
1997). Both cell lines were grown in Dulbecco’s modified Eagle’s
medium containing 10% dialyzed FBS (mol. wt. cut-off 10,000; from
Sigma-Aldrich), 2 mM glutamine, 100 units/ml penicillin, and 100 mg/ml
streptomycin within 10 passages. The culturemedium for the transfected
cell line was supplemented with geneticin (250mg/ml). Cells were seeded
on 24-well poly-D-lysine–coated plates at 100,000 cells/well 48–72 hours
before experimentation.
Metformin Cellular Uptake
Single Transporter-Expressing CHO Cells. Transport experi-
ments using CHO cells were performed as described previously (Ming
et al., 2009). Briefly, CHO cells were seeded at 100,000 cells/cm2 in
sterile 24-well polycarbonate plates, and transport experiments were
performed between days 5 and 7 postseeding. The CHO cell
monolayers were preincubated with transport buffer (Hanks’ bal-
anced salt solution with 25 mM D-glucose and 10 mMHEPES, pH 7.2)
for 30 minutes at 37°C. Uptake experiments were initiated by
replacing the buffer solution with 300 ml of dosing solution. Uptake
was terminated at the indicated time points by aspirating the donor
solution and washing the monolayer 3 with 1 ml of 4°C transport
buffer. The cell monolayers were allowed to dry, and 500 ml of lysis
buffer (0.1 N NaOH with 0.1% SDS) was added to each well. Plates
were shaken for 3 hours to ensure total lysis of the cell monolayer.
Protein content of the cell lysate was determined by the bicinchoninic
acid protein assay (Pierce, Rockford, IL) with bovine serum albumin
as a standard. Radiolabeled compound in the cell lysate was analyzed
by liquid scintillation spectrometry and the rate of initial uptake of
each compound was determined. The rate for metformin uptake into
mock CHO cells was subtracted from the uptake rates obtained in
each OCT-expressing cell line to obtain a corrected uptake rate
reflective of only the carrier-mediated transport of metformin.
Caco-2 Cell Monolayers. AP uptake of metformin was measured
using methods outlined previously (Proctor et al., 2008) with minor
deviations. Inhibition of [14C]metformin (0.15 mCi/ml, 10 mM, 5 minutes)
AP uptake in Caco-2 cells was assessed by measuring uptake in the
absence (control) or presence of cimetidine (5 mM), mitoxantrone
(25mM), corticosterone (150mM), desipramine (200mM),MPP1 (5mM),
paroxetine (0.1 mM), and HC3 (1 mM). Cell monolayers were
preincubated for 30 minutes in transport buffer in the presence of the
inhibitors outlined previously or by vehicle control bathing both the AP
and BL compartments. AP uptake experiments were initiated by re-
placing the buffer solution in the AP donor compartmentwith transport
buffer containing the substrate in the presence of an inhibitor or vehicle
control. Uptake was terminated during the linear uptake range in Caco-2
cell monolayers (5 minutes) by washing the AP and BL compartments
three times with 0.75 ml of 4°C transport buffer. The cell monolayers
were allowed to dry, excised from the insert, lysed and analyzed as
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previously described, and the initial uptake rate of metformin was
determined.
SERT-Expressing HEK 293 Cells. Uptake of [14C]metformin by
SERT was determined in SERT-transfected HEK 293 cells and cor-
rected for [14C]metformin uptake in control HEK 293 cells. Following
uptake, the cells were washed 3 with 4°C transport buffer, 500 ml of
lysis buffer was added to the wells, and the cells were then incubated
for 3 hours with shaking before counting the radioactivity. The
apparent kinetic parameters Km and Vmax for metformin uptake were
estimated to be ∼463 mM and ∼400 nmol/min per milligram protein,
respectively. To determine whether this low affinity was due to
surface binding of metformin, a [14C]metformin surface binding assay
was performed. The cells were washed with 1 M unlabeled metformin
following the 4°C transport buffer wash, and the amount of surface
bound [14C]metformin released into the wash solution was quantified.
After washing with metformin solution, the cells were lysed as de-
scribed previously, the intrinsic uptake of [14C]metformin was quan-
tified by scintillation spectrometry, and the intrinsic kinetic parameters
were determined.
Generation of PMAT-Knockdown Caco-2 Clones
PMAT-knockdown Caco-2 clones were generated using a method
similar to that used to generate OCT1-knockdown Caco-2 clones (Han
et al., 2013). The PMAT-specific small interfering RNA sequence
(sense strand: 59-CAGCUUCAUCACGGACGUG-39; antisense strand:
59-CACGUCCGUGAUGAAGCUG-39) was obtained from published
reports (Engel et al., 2004). The antisense and sense oligonucleotides
were linked together with a hairpin loop, and annealed with the
respective complementary DNA oligonucleotides. Each resulting
double-stranded DNA was inserted into BamHI and HindIII sites of
the pRNATin-H1.2/Hygro vector (GenScript, Piscataway, NJ) to
generate the short hairpin RNA plasmid. Caco-2 cells at 90% con-
fluence were transfected with the short hairpin RNA plasmid, using
the Nucleofector System (Amaxa, Gaithersburg, MD) according to the
manufacturer’s protocol. Transfectants were selected with 0.2 mg/ml
hygromycin B for 3 weeks, and screened by quantitative real-time
polymerase chain reaction for OCT1 or PMAT expression. Three clones
exhibiting, normal morphology and growth rate as well as the lowest
PMAT gene expression were chosen for subsequent functional studies.
Real-Time Quantitative Reverse-Transcription Polymerase
Chain Reaction
The mRNA expression of human OCT1–3, PMAT, MATE1–2, CHT,
and CTL1–5 relative to 18s rRNA in Caco-2 cells and human intestine
was determined using quantitative reverse-transcription polymerase
chain reaction that was conducted using established methods
(Holmes et al., 2006) with minor deviations as described previously
(Han et al., 2013).
Western Blot Analysis
Wild-type Caco-2 cells and PMAT-knockdown Caco-2 cells were
washed twice with ice-cold phosphate-buffered saline and lysed in the
radioimmunoprecipitation assay buffer system using a sonicator.
Human jejunal tissues (approximately 50 mg) were washed with
water, and homogenized in the radioimmunoprecipitation assay
buffer system. Protein concentrations of cell and tissue samples were
determined by the bicinchoninic acid assay. Protein from cells (30 mg
per lane) and tissues (40 mg per lane) were subjected to Western blot
analyses as previously described (Han et al., 2013) using primary
antibodies against OCT1, PMAT, SERT, and CHT. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) served as the loading control.
Data Analysis
AMichaelis-Menten equation with one saturable component was fit
to the corrected initial uptake rate data, which represented only




whereC is the metformin concentration, Vmax is the maximal velocity,
and Km is the Michaelis-Menten constant.
The inhibitory potency (e.g., the IC50 value) was determined for
each inhibitor across the transporter expressing cell line. The fol-




where V is the uptake rate in the presence of inhibitor I; Vo is the
uptake rate in the absence of inhibitor; IC50 is the inhibitor con-
centration to achieve 50% inhibition; and n is the Hill coefficient. The
uptake kinetic parameter and the IC50 curve parameter estimates
were obtained by nonlinear regression analysis with GraphPad Prism
5 (La Jolla, CA). The IC50 data for [
14C]metformin uptake into
transporter expressing cells and Caco-2 cells were reported relative to
the control. Statistical significancewas evaluated by one-way analysis
of variance followed by the Bonferroni post-hoc test unless otherwise
noted. Data represent mean 6 S.D; n 5 3 unless otherwise noted;
*P , 0.05, **P , 0.01, and ***P , 0.001 compared with the control;
and #P , 0.05 compared with each other.
Results
Transporter mRNA Expression in Caco-2 Cell Mono-
layers and Human Intestinal Tissue. Figure 1 shows the
gene expression levels of the transporters implicated in
metformin transport as well as other cation-selective trans-
porters in Caco-2 cells and, for comparison, in human in-
testinal tissue. In Caco-2 cells, CTLs and SERT are the most
highly expressed transporter genes relative to other cation-
selective transporters examined, with PMAT and OCT3 genes
also highly expressed. OCT1, OCT2, MATEs, and CHT are
expressed at low but detectable levels (Fig. 1A). In human
intestinal tissue, PMAT and OCT3 genes are highly expressed
relative to the other transporters. SERT and CTL genes are
also expressed in human intestine tissue, although their
expression levels are not as high as those observed in Caco-2
cell monolayers; The OCT1 gene is expressed at low levels as
in Caco-2 cell monolayers. OCT2, MATE2, and CHT mRNA
expression was not detected in human intestine (Fig. 1B).
Selectivity of a Panel of Inhibitors toward OCT1-,
OCT2-, and OCT3-Mediated Metformin Uptake in
Single Transporter-Expressing CHO Cells. Because
OCTs play a major role in hepatic uptake and renal elim-
ination of metformin, it was reasonable to expect that these
transporters would contribute to AP uptake of metformin,
although these were not the most highly expressed transporters
in the human intestinal tissue or Caco-2 cell monolayers (Fig. 1).
Selectivity and potency of inhibitors of metformin uptake by
OCT1–3 was evaluated in relation to the substrate activity of
metformin in a panel of CHO cells that singly expressed OCT1,
OCT2, OCT3, and OCTN2. These studies showed that metfor-
min was a substrate for OCT1, OCT2, and OCT3 with apparent
Km values of 3.16 0.3, 0.66 0.1, and 2.66 0.2 mM, respectively
(Supplemental Fig. 1). This confirms previous reports regarding
substrate affinities of these transporters formetformin (Koepsell
et al., 2007). In contrast, metformin uptake into OCTN2-
expressing CHO cells was inefficient and not significantly
different from uptake into the mock CHO cells (Supplemental
Fig. 1), thus providing evidence thatmetformin is not a substrate
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for OCTN2. Therefore, this transporter was omitted in sub-
sequent studies. The curves depicting inhibition of metformin
uptake into OCT1-, OCT2-, and OCT3-expressing CHO cells by
the OCT inhibitors, mitoxantrone, corticosterone, cimetidine,
and desipramine are shown in Fig. 2, A–D, and the IC50 values
are summarized in Table 1. Mitoxantrone, reported to be an
OCT1-specific inhibitor (Koepsell et al., 2007), was a potent
inhibitor of OCT1 with an IC50 value of 3.0 6 0.8 mM, which is
40- to 60-fold lower than the estimated IC50 values for OCT2 and
OCT3 (Fig. 2A; Table 1). Corticosterone and desipramine were
also strong inhibitors of OCT1-mediated metformin uptake with
similar inhibitory potency (e.g., IC50 values ,4 mM), although
not as selective for OCT1 asmitoxantrone. In fact, corticosterone
is a selective inhibitor of OCT3 over OCT1 (.20-fold) and OCT2
(.8-fold). Corticosterone and desipramine were the most potent
OCT2 inhibitors with IC50 values estimated to be less than 3mM
(Fig. 2, B and D; Table 1), but neither was a selective OCT2
inhibitor. Cimetidine is another potent inhibitor of OCT1-3 (IC50
values 10–21mM;Table 1); notably, it has a 10- to 20-fold greater
inhibitory potency toward another cation transporter, MATE1,
with the reported IC50 value forMATE1 of 1.160.3mM(Fig. 2C;
Table 1) (Tsuda et al., 2009).
Contribution of OCTs and Other Cation Transport-
ers toward AP Uptake of Metformin into Caco-2 Cell
Monolayers. The data for inhibition of OCT1–3 by mito-
xantrone, cimetidine, corticosterone, and desipramine (Fig. 2,
A–D; Table 1), combined with the previously reported data for
inhibition of MATE1 (Tsuda et al., 2009) and PMAT (Engel
andWang, 2005), were used to develop a decision tree to estimate
the contribution of these transporters toward metformin AP
uptake into Caco-2 cells. The inhibitors were used singly or
as a cocktail for estimating the relative contributions of these
transporters in the AP uptake of metformin. The concentration
selected for each inhibitor was at least 4-fold greater than the
estimated IC50 value for metformin uptake by that transporter,
and at least 2-fold lower than the IC50 values for othermetformin
transporters. At the selected inhibitor concentrations, the target
transporters were inhibited by.80% with,20% inhibition of
the nontarget transporters. Figure 2, E and F, depicts the
chemical inhibition scheme deployed in elucidating the in-
volvement of specific cation-selective transporters in the AP
uptake of metformin in Caco-2 cell monolayers. Cell viability
and monolayer integrity were not affected in any of the
chemical inhibition studies presented here as measured by
TEER prior to and immediately after transport studies (data
not shown).
Inhibition by cimetidine (5 mM) had no effect on the AP
uptake of metformin in Caco-2 cells, which eliminated the
contribution of MATE1 in mediating AP uptake of metformin.
Mitoxantrone (25 mM) decreased the AP uptake of metformin
to 74 6 8% (P , 0.01) of the control. Although it has been
previously reported that mitoxantrone is an inhibitor of
MATE1 [with either MPP1 or 4-(4-(dimethylamino)styryl)-
N-methylpyridinium iodide as substrates] (Grottker et al.,
2011; Wittwer et al., 2013), we have concluded that the ∼25%
decrease in the AP uptake ofmetformin caused bymitoxantrone
must be due to inhibition of OCT1 because cimetidine did not
inhibit metformin AP uptake. Corticosterone (150 mM) in-
hibited AP uptake of metformin by ∼25%, reducing the AP
uptake to 73% 6 3% (P , 0.01) of the control. The inhibitory
effects of mitoxantrone on OCT1-mediated metformin uptake
and of corticosterone on OCT1–3-mediated metformin uptake
into Caco-2 cell monolayers were not significantly different,
providing evidence that OCT2 and 3 do not contribute to
the AP uptake of metformin in Caco-2 cell monolayers.
Desipramine (200 mM) reduced the AP uptake of metformin
by ∼65% (P , 0.001), which accounts for an additional ∼40%
reduction in metformin AP uptake over the ∼25% reduction
observed with corticosterone. These data suggest that PMAT
also contributes to the AP uptake of metformin in Caco-2 cell
monolayers to approximately the same (or greater) extent as
OCT1 (Fig. 2, D and E). MPP1 (5 mM), which inhibits all
transporter-mediated uptake (Koepsell et al., 2007), reduced
metformin uptake by ∼80%, indicating that at least 80% of
metformin AP uptake into Caco-2 cell monolayers is mediated
by cation-selective transporters; the remaining 20% apparent
uptake may be due to nonspecific binding of metformin to the
cell surface because uptake due to passive diffusion is un-
likely. A significant difference (P , 0.05) in the inhibitory
effects of desipramine and MPP1 suggests that there may be
another unknown transporter(s) contributing to the AP up-
take of metformin in Caco-2 cell monolayers.
Fig. 1. Expression levels of cation-selective transporter genes in Caco-2 cell monolayers (A) and human intestine tissue (B). Data represent mean 6
S.D., n = 3.
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SERT and CHT Contribute to the AP Uptake of
Metformin in Caco-2 Cell Monolayers. To identify the un-
known transporter(s) involved in the AP uptake of metformin,
the affinity of metformin for SERT was evaluated because
SERT is known to transport organic cations and is expressed in
Caco-2 cells (Martel et al., 2003; Hilber et al., 2005; Seidel et al.,
Fig. 2. Relative contributions of cation-selective transporters to the AP uptake of metformin into Caco-2 cell monolayers determined using a novel
chemical inhibition scheme. Inhibition of metformin uptake (10 mM, 5 minutes) into OCT1-, 2-, and 3-expressing CHO cells by mitoxantrone (A),
corticosterone (B), cimetidine (C), and desipramine (D). Data represent mean 6 S.D., n = 3. Inhibition curves were fit to corrected uptake rate in the
presence of varying concentrations of each inhibitor. (E) Chemical inhibition scheme to determine the contributions of transporters to metformin AP
uptake in Caco-2 cell monolayers. (F) Inhibition of metformin AP uptake (10 mM, 5 minutes) in Caco-2 cell monolayers in the presence of chemical
inhibitors shown in (E). Data represent mean 6 S.D., n = 3. **P , 0.01, ***P , 0.001 compared with the control; #P , 0.05 compared with each other.
TABLE 1
IC50 values for inhibitors of metformin uptake via cation-selective transporters
The IC50 values reported were experimentally determined except for those entries in which literature values are cited.
Inhibitor
IC50 Values (Mean 6 S.D.)
OCT1 OCT2 OCT3 SERT CHT CTLs
mM
Mitoxantrone 3.0 6 0.8 135.0 6 12.0 174.0 6 19.0 977.2 6 1.2 N/A N/A
Cimetidine 20.9 6 1.4 16.6 6 1.3 9.8 6 1.3 N/A N/A N/A
Corticosterone 3.2 6 0.5 1.3 6 0.1 0.2 6 0.1 N/A N/A N/A
Paroxetine 1.0 6 0.2 11.9 6 1.2 6.4 6 1.3 0.0060 6 0.00059 N/A N/A
Desipramine 2.2 6 0.4 2.4 6 0.2 3.8 6 0.3 0.054 6 0.0042a N/A N/A
HC3 112.2 6 1.5 131.8 6 1.4 524.8 6 1.7 70.8 6 1.2 0.004b ~100c
N/A, not available.
aBarker et al., 1994.
bApparsundaram et al., 2000.
cLockman and Allen, 2002.
Four Transporters in Metformin Apical Uptake in Caco-2 Cells 523
2005). Metformin uptake in SERT-HEK 293 cells showed
linearity up to 2 minutes, followed by nonlinear uptake; while
metformin uptake in control HEK 293 cells was significantly
lower and linear up to 30 minutes (Fig. 3A). The apparent
Km value for SERT-mediated metformin uptake was estimated
at 4 mM (Fig. 3B).
Paroxetine, a selective serotonin reuptake inhibitor with
a reported Ki for SERT of 0.8 nM (Owens et al., 1997),
inhibited OCT1-, 2-, 3-, and SERT-mediated metformin
uptake in single transporter-expressing cell systems with
IC50 values of 1.06 0.2 mM, 11.96 1.2 mM, 6.46 1.3 mM, and
6.06 0.6 nM, respectively. Hence, a paroxetine concentration
of 0.1 mM was used to selectively inhibit SERT, without
inhibiting OCTs (Table 1).
The contribution of SERT to metformin AP uptake in Caco-2
cell monolayers was evaluated using chemical inhibitors at
concentrations outlined in the modified chemical inhibition
scheme (Fig. 3D) with the results presented in Fig. 3E. The
estimated IC50 value for inhibition of metformin uptake into
SERT-expressing cells by mitoxantrone was 977.2 6 1.2 mM
(Supplemental Fig. 2; Table 1); therefore, we can conclude
that mitoxantrone at 25 mM inhibited only OCT1 and did not
significantly inhibit SERT. The selective inhibitor of SERT,
paroxetine, decreased metformin AP uptake into Caco-2 cell
monolayers by ∼20%. Because desipramine also inhibits SERT
with a Ki value of 54 6 4.2 nM (Barker et al., 1994), ∼65%
decrease in metformin AP uptake by desipramine likely in-
cludes inhibition of SERT in addition to the inhibition of
OCT1 and PMAT. Thus, 65% inhibition of metformin uptake
by desipramine would suggest OCT1, PMAT, and SERT
contribute ∼25, ∼20, and ∼20%, respectively, to metformin
AP uptake.
To account for ∼15% remaining transporter-mediated
uptake of metformin, the choline transporter system, which
includes CHT and CTL1–5, was considered as a possible
candidate. Studies have shown that a selective CHT inhibitor,
HC3 can inhibit CHT with greater potency (IC505 4 nM) than
CTLs (∼100 mM) (Apparsundaram et al., 2000; Lockman and
Allen, 2002). To determine whether HC3 can also inhibit
OCTs and SERT, the potency of HC3 for inhibition of OCTs
and SERT was investigated (Fig. 4A). The IC50 values for
OCT1-, 2-, 3-, and SERT-mediated metformin uptake are
112.2 6 1.5, 131.8 6 1.4, 524.8 6 1.7, and 70.8 6 1.2 mM,
respectively (Table 1). Therefore, 1 mM HC3 can be used to
selectively inhibit CHT-mediated metformin uptake without
affecting the other transporters. In a modified chemical
inhibition scheme (Fig. 4B), HC3 caused ∼15% decrease in
the AP uptake of metformin relative to control cells (Fig. 4C).
Desipramine and HC3 together inhibited ∼80% of the AP
uptake of metformin, which was not significantly different
from the inhibitory effect of 5 mM MPP1 (Fig. 4C). These
results suggested the involvement of CHT, with a relative
contribution of ∼15% to the AP uptake of metformin, which
combined with OCT1, PMAT, and SERT, accounts for all of
the transporter-mediated uptake of metformin across the AP
membrane in Caco-2 cell monolayers.
Fig. 3. SERT is a metformin transporter and contributes to the AP uptake of metformin in Caco-2 cell monolayers. (A) Uptake of metformin (1 mM) as
a function of time in SERT- transfected HEK 293 cells (closed symbols) and HEK 293 control cells (open symbols). (B) Uptake of metformin (2 minutes) as
a function of concentration in SERT-HEK 293 cells, corrected for surface binding and uptake of metformin in control HEK 293 cells. A Michaelis-Menten
equation with one saturable component was fit to the corrected uptake rate data and the estimated Km and Vmax values are presented. (C) Inhibition
curves depicting metformin uptake (10 mM, 5 minutes) by OCTs and SERT in the presence of paroxetine. (D) Modified chemical inhibition scheme to
determine the contributions of OCT1, PMAT, and SERT tometformin uptake into Caco-2 cell monolayers. (E) Inhibition of metformin AP uptake (10 mM,
5 minutes) in the presence of inhibitors considered in (D). Data represent mean 6 S.D., n = 3. *P , 0.05, **P , 0.01, ***P , 0.001 compared with the
control; #P , 0.05 compared with each other.
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Protein Expression of the Four Metformin Trans-
porters in Caco-2 Cell Monolayers and Human In-
testine. The genes of all four transporters that have a role in
metformin uptake across the AP membrane of Caco-2 cell
monolayers are expressed in these cells (Fig. 1). However, it is
important to determine if the transporter proteins are also
expressed in Caco-2 cell monolayers. Western blot analysis
showed that all four transporters implicated in metformin
transport, i.e., OCT1, PMAT, SERT, and CHT, are expressed
in Caco-2 cells (Fig. 4E). PMAT and SERT exhibited higher
protein expression levels than OCT1 and CHT (Fig. 4E).
Furthermore, the analysis showed that these transporter
proteins are also expressed in human jejunal tissue (Fig. 4F).
The protein expression level for these transporters in human
jejunal tissue was much lower than that in Caco-2 cells. As
in Caco-2 cells, PMAT and SERT exhibited higher protein
expression levels than OCT1, but unlike Caco-2 cells, CHT
protein expression in the human jejunal tissue was barely
visible (Fig. 4F).
Confirmation of PMAT Contribution to Metformin
AP Uptake with a Stable PMAT-Knockdown Caco-2
Cell Construct. Since the contribution of PMAT in the AP
uptake of metformin in Caco-2 cell monolayers was derived
indirectly by using a combination of inhibitors, neither of
Fig. 4. Inhibition by HC3 reduced the initial AP uptake rate of metformin. (A) Inhibition of metformin uptake by HC3 into OCT1-, 2-, 3- and SERT-
expressing cells. (B) Modified chemical inhibition scheme to determine the relative contribution of OCT1, PMAT, SERT, and CHT to metformin
AP uptake into Caco-2 cell monolayers. (C) Inhibition of metformin AP uptake (10 mM, 5minutes) by inhibitors considered in (B). Data represent mean6
S.D., n = 3. *P , 0.05, **P , 0.01, ***P , 0.001 compared with the control; #P , 0.05 compared with each other. (D) Chemical structures of metformin
and choline. (E and F) Protein expression levels of four metformin transporters in Caco-2 cell monolayers (E), and in human intestinal tissue (F) as
determined by Western blot analysis.
Four Transporters in Metformin Apical Uptake in Caco-2 Cells 525
which was selective for PMAT, it was important to confirm
this result using a distinctly different approach. Hence,
PMAT-knockdown Caco-2 cells were created in which three
clones with normal morphology and growth rate (2, 9, 24),
exhibited attenuation of the PMAT mRNA expression by
.70% of the control (Fig. 5A) with a corresponding reduction
in the PMAT protein expression (Fig. 5B). OCT1-knockdown
clones [construct 1-clone 43 (1-43), construct 3-clone 21 (3-21),
and construct 3-clone 27 (3-27)] with 70% reduction in the
OCT1 mRNA expression (corresponding reduction in OCT1
protein expression has been shown previously) (Han et al.,
2013) (Fig. 5C) were identified and used as the positive control
for the studies with PMAT-knockdown Caco-2 cells. The AP
uptakes of metformin in PMAT-knockdown (Fig. 5D) and
OCT1-knockdown (Fig. 5E) Caco-2 cell monolayers were ∼40
and 20%, respectively, lower than that in the corresponding
wild-type cells; and this is consistent with 25% reduction in
metformin AP uptake caused by mitoxantrone, an OCT1-
specific transporter at the concentration employed.
Discussion
Metformin is known to be a substrate for multiple trans-
porters in the liver/kidney, and many of these transporters
are likely expressed in the AP membrane in Caco-2 cell
monolayers. Therefore, elucidation of the relative contribution
of individual transporter(s) to metformin AP uptake required
the use of a highly selective inhibitor for each transporter.
Alternatively, one could use the relative activity factor method
proposed by Hirano et al. (2004), using selective substrates for
each transporter to estimate the contribution of transporters to
uptake of drugs when multiple transporters are involved.
However, these methods are often not feasible, especially for
cation-selective transporters where the inhibition curves often
overlap across different transporters. Therefore, a novel ap-
proach was conceived in which the use of available transporter-
specific inhibitors was combined with the use of a cocktail of
inhibitors with known but overlapping inhibitory potencies
toward multiple transporters (depicted in Figs. 2–4).
The transporters that were initially considered are
OCT1–3, OCTN2, MATE1, and PMAT (Fig. 2E). Surprisingly,
uptake studies with metformin in OCTN2-expressing CHO
cells revealed that metformin is not a substrate for this
transporter (Supplemental Fig. 1). This finding is highly
significant in that it rules out metformin transport by one of
the most highly expressed AP cation-selective transporters in
both Caco-2 cells and human intestine (Elimrani et al., 2003)
as well as in the heart, liver, and kidney (Tamai et al., 1998;
Wu et al., 1999; Hilgendorf et al., 2007). The studies with the
initial inhibition scheme provided evidence that OCT1 and
PMAT were involved in metformin AP uptake and ruled out
OCT2, OCT3, and MATE1 (Fig. 2).
The chemical inhibition studies (Fig. 2) revealed that a
significant component of carrier-mediated uptake was un-
accounted for (Fig. 2F), suggesting that in addition to OCT1
and PMAT, another transporter(s) is involved in metformin
AP uptake. Hence, other proteins known to transport cations
were considered, and SERT was chosen for further investiga-
tion for reasons outlined subsequently. SERT is expressed in
both AP and BL membranes, although expression on the AP
Fig. 5. Metformin AP uptake into PMAT- and OCT1-knockdown Caco-2 cells. (A–C) Expression levels of the PMAT gene (A) and protein (B) in PMAT-
knockdown clones, and the OCT1 gene (C) in OCT1-knockdown clones of Caco-2 cells relative to the control (wild-type Caco-2 cells); gene expression data
represent mean 6 S.D., n = 3. *P , 0.05, **P , 0.01 compared with the control, and protein expression data are from n = 1. (D and E) Metformin AP
uptake (10 mM, 5 minutes) into (D) PMAT- and (E) OCT1-knockdown clones relative to the control (wild-type Caco-2 cells). Data represent mean6 S.D.,
n = 3. *P , 0.05, **P , 0.01 compared with the control.
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side is predominant in the intestine and Caco-2 cell monolayers
(Wade et al., 1996; Martel et al., 2003; Gill et al., 2008), and it
functions as an uptake transporter (Nelson and Rudnick,
1979). The endogenous substrate of SERT is serotonin; how-
ever, SERT and other OCTs share substrates. In OCT3- and
PMAT-transfected HEK 293 cells, both these transporters
can mediate uptake of serotonin (Duan and Wang, 2010).
Additionally, in SERT-transfected HEK 293 cells, SERT can
mediate uptake of several organic cations such as tyramine,
MPP1, and para-chloroamphetamine (Hilber et al., 2005). Thus,
it was reasonable to consider SERT as the missing transporter
in metformin AP uptake.
In this study, metformin was shown to be a substrate for
SERT with an apparent Km of approximately 4 mM, which is
similar to the metformin Km for OCT1 and OCT3. This is the
first report of metformin being transported by SERT. A second
chemical inhibition scheme was employed (Fig. 3D) in which
paroxetine, a potent serotonin-selective reuptake inhibitor,
was deployed. Studies with this inhibition scheme (Fig. 3)
have suggested that approximately 20% of metformin uptake
into Caco-2 cell monolayers is mediated by SERT. Interest-
ingly, studies deploying the new chemical inhibition scheme
(Fig. 3) did not account for a significant difference (∼15%) in
the inhibition of metformin AP uptake by desipramine and
MPP1, and thus left open the possibility that yet another
transporter contributes to metformin AP uptake into Caco-2
cell monolayers.
We considered choline transporters in our search for the
identity of the yet unknown transporter that contributes to
∼15% of metformin AP uptake into Caco-2 cell monolayers.
This was because choline is a hydrophilic quaternary amine
with a permanent positive charge, thus resembling metformin
in key structural features (Fig. 4D) (Werner and Bell, 1921;
Ing, 1949). The choline transporter system, which includes
CHT and CTLs, plays a significant role in the intestinal ab-
sorption of this essential nutrient (Sanford and Smyth, 1971;
Herzberg and Lerner, 1973; Kuczler et al., 1977; Kamath
et al., 2003). HC3 (1 mM), a specific inhibitor of CHT (IC50 5
4 nM; Apparsundaram et al., 2000), inhibited metformin AP
uptake into Caco-2 cell monolayers by ∼15% (Fig. 4), sup-
porting a role of CHT in metformin uptake. Thus, the AP
uptake of metformin in Caco-2 cell monolayers was reex-
amined by including HC3 in the inhibition scheme (Fig. 4). As
expected, HC3 reduced metformin AP uptake by ∼15%, and
a mixture of desipramine and HC3 completely abolished all
carrier-mediated uptake of metformin in Caco-2 cells similar
to the inhibition observed withMPP1. Direct evidence for CHT
involvement in metformin transport is still lacking; however,
the inhibition data in Fig. 4 strongly suggest the involvement of
this transporter in metformin AP uptake into Caco-2 cell
monolayers. The other choline transport proteins, CTL1–5,
which are highly expressed in the intestine, are not inhibited
by HC3 at 1 mM (IC50 values in the 100 mM range) (Lockman
and Allen, 2002), and therefore are likely not involved in
metformin AP uptake.
Of the four transporters implicated, the contribution of
PMAT toward metformin AP uptake into Caco-2 cell mono-
layers was determined based on a process of elimination
without the use of a selective inhibitor. To confirm the in-
volvement of PMAT and the validity of our chemical inhibition
scheme, stable PMAT-knockdown Caco-2 clones were gener-
ated using an established small interfering RNA sequence
(Engel et al., 2004). OCT1-knockdown Caco-2 clones generated
previously (Han et al., 2013) were used as a positive control. In
both PMAT- and OCT1-knockdown cells, metformin AP uptake
was decreased by ∼40 and ∼20%, respectively (Fig. 5, D and E).
This finding, confirming the role of PMAT in metformin
AP uptake, is novel in that this is the first report of PMAT
expression and function in Caco-2 cell monolayers. Together,
these studies corroborate chemical inhibition data that have
provided evidence for the contribution of PMAT toward
metformin AP uptake in Caco-2 cell monolayers.
The studies in this work show that a judicious use of a
cocktail of inhibitors can elucidate the contributions of several
transporters in the uptake or transport of drugs across bio-
logic barriers, and uncover the role of previously unknown
transporters in the transport of a given drug. This is the first
report in which the contributions of four different trans-
porters (OCT1, PMAT, SERT, and CHT) in metformin AP
uptake into Caco-2 cell monolayers (Fig. 6) was established
through a series of studies showing gene and protein ex-
pression of these transporters, metformin uptake, and in-
hibition of the uptake using a cocktail of uptake inhibitors. It
is noteworthy that protein expression of PMAT and SERT is
higher in human jejunal tissue, with lower expression of
OCT1 and trace expression of CHT (Fig. 4F). Establishing the
role of these transporters in Caco-2 cells, and by implication in
human intestinal epithelium, is a significant finding consid-
ering that metformin has been in clinical use for decades
without any recognition that its intestinal absorption may
involve multiple intestinal transporters. Elucidation of the
role of these transporters in the intestinal absorption of
metformin after oral administration to humans will require
consideration and modeling of transporter-mediated uptake
(and efflux) kinetics, the expression of these transporters and
varying metformin concentrations along the length of the
intestine, and mechanisms that drive AP uptake and efflux of
metformin by each transporter (e.g., sodium dependence for
SERT, membrane potential for OCT1, etc.). This work, and
Fig. 6. Schematic representation of the contributions of cation-selective
transporters to metformin AP uptake in Caco-2 cell monolayers. OCT1,
PMAT, SERT, and CHT are responsible for 25%, 20%, 20%, and 15% of the
AP uptake of metformin in Caco-2 cell monolayers, respectively. Passive
processes and nonspecific binding likely contribute to the remaining ∼20%
of the apparent uptake measured.
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future studies that will be conceived based on this work, will
yield valuable insight into the mechanisms responsible for
the dose-dependent and variable absorption (Noel, 1979;
Tucker et al., 1981), intestinal accumulation, and associated
pharmacology/adverse effects (Stepensky et al., 2002; Bailey
et al., 2008) of metformin. Furthermore, these findings will
lead to critical reexamination of metformin’s potential to
cause intestinal drug-drug interactions. The high dose (e.g.,
500–1000 mg) of metformin may affect oral absorption of co-
administered cationic drugs in which absorption is dependent
on transporters.
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